NEXI (NexImmune) Total Stockholders Equity : $0.92 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is NexImmune Total Stockholders Equity?

NexImmune's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $0.92 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. NexImmune's Book Value per Share for the quarter that ended in Jun. 2024 was $0.66. The ratio of a company's debt over equity can be used to measure how leveraged this company is. NexImmune's Debt-to-Equity for the quarter that ended in Jun. 2024 was 0.00.

NexImmune Total Stockholders Equity Historical Data

The historical data trend for NexImmune's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NexImmune Total Stockholders Equity Chart

NexImmune Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

10.61

-15.75

83.76

32.30

3.51

NexImmune Quarterly Data
	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Total Stockholders Equity	Get a 7-Day Free Trial															17.00	8.25	3.51	2.97	0.92

NexImmune (OTCPK:NEXI) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

NexImmune's Book Value per Share for the quarter that ended in Jun. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(0.921	-	0)	/	1.395
	=	0.66

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

NexImmune's Debt-to-Equity for the quarter that ended in Jun. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0.921
	=	0.00

NexImmune Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of NexImmune's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

NexImmune Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NexImmune Inc (OTCPK:NEXI) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

9119 Gaither Road, Gaithersburg, MD, USA, 20877

Website

https://www.neximmune.com

NexImmune Inc is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.

Executives

Alan S. Roemer	director	C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Timothy Stover	officer: VP, Corporate Controller	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Sol J Barer	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Zhengbin Yao	director	10301 STELLA LINK ROAD, HOUSTON TX 77025
Leena Gandhi	director	C/O NEXIMMUNE, 9119 GAITHER ROAD, GAITHERSBURG MD 20878
Timothy Bertram	director	C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403
Paul D'angio	director	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Grant Verstandig	director	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Mathias Oelke	officer: Chief Science Officer	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20878
Kristi Jones	officer: Chief Operating Officer	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Jerome B Zeldis	officer: EVP of R&D	8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Scott Carmer	director, officer: President and CEO	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
John Trainer	officer: Chief Financial Officer	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Robert Douglas Knight	officer: Chief Medical Officer	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877